C12N 15/1132
Against retroviridae
Official title: {against retroviridae, e.g. HIV}
C12N15/1132 (Against retroviridae) appears on 317 US grants and 390 published applications in this corpus.
Search patents in C12N- Granted patents
- 317
- Published applications
- 390
- Assignees
- 182
- Inventors
- 607
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 5 | 0 |
| 1993 | 5 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 9 | 0 |
| 1997 | 21 | 0 |
| 1998 | 18 | 0 |
| 1999 | 18 | 0 |
| 2000 | 19 | 0 |
| 2001 | 12 | 4 |
| 2002 | 19 | 7 |
| 2003 | 5 | 32 |
| 2004 | 6 | 23 |
| 2005 | 2 | 50 |
| 2006 | 5 | 11 |
| 2007 | 5 | 13 |
| 2008 | 3 | 24 |
| 2009 | 2 | 20 |
| 2010 | 21 | 7 |
| 2011 | 16 | 19 |
| 2012 | 14 | 13 |
| 2013 | 6 | 11 |
| 2014 | 9 | 7 |
| 2015 | 13 | 12 |
| 2016 | 6 | 13 |
| 2017 | 7 | 17 |
| 2018 | 9 | 20 |
| 2019 | 14 | 21 |
| 2020 | 6 | 16 |
| 2021 | 11 | 13 |
| 2022 | 6 | 8 |
| 2023 | 6 | 7 |
| 2024 | 6 | 11 |
| 2025 | 2 | 11 |
| 2026 | 3 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Comb shaped antivirals ending with or without chain terminating bases7 Jul 2026US 12,674,163 B2
- HIV-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents2 Jun 2026US 12,644,121 B2Board of Regents of the University of Nebraska
- Pre-immunization and immunotherapy29 Jul 2025US 12,370,253 B2American Gene Technologies International Inc.
- Methods and compositions for RNA-guided treatment of HIV infection18 Mar 2025US 12,251,429 B2Temple University of the Commonwealth System of Higher Education
- Hypoimmunogenic biomimetic nanovesicle gene editing system for hiv infection25 Dec 2025US 2025/0387515 A1
- Conjugates of Guide RNA-Cas Protein Complex18 Dec 2025US 2025/0381301 A1
- Lipid nanoparticle formulations and methods of use thereof27 Nov 2025US 2025/0360083 A1Board of Regents of the University of Nebraska
- Tat-induced crispr/endonuclease-based gene editing7 Aug 2025US 2025/0250562 A1Temple University of the Commonwealth System of Higher Education
- T-cells for anti-hiv car-t therapy and methods of use15 May 2025US 2025/0154457 A1City of Hope
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Inhibitors for replication of retroviruses and for the expression of oncogene products619US 5,276,019 AThe United States of America as represented by the Department of Health and Human Services · 1994